L dopa methyl ester hcl

To create the 6-OHDA lesion, rats were anesthetized with sodium pentobarbital (60 mg/kg) and then immobilized in a stereotaxic frame to target the unilateral SNpc (coordinates AP-5.2, ML-2.1, DV-8.0) relative to bregma. A single 6-OHDA (5 μg/μL, diluted in normal saline containing 0.02% ascorbic acid; Sigma) solution was injected over 3 min with an infusion rate of 1 μL/min, followed by 3 min of equilibrium before retracting the needle. All rats were allowed to a 21-day recovery period before experiment start. Then, intraperitoneal injection of L-DOPA [L-DOPA methyl ester HCl (5 mg/kg) combined with benserazide HCl (2.5 mg/kg) diluted in 0.9% saline; Sigma] and intragastrical administration of RES (20 mg/kg, diluted in 0.1% carboxymethylcellulose sodium aqueous solution; Sigma) were performed daily.

For all in vitro experiments, SKF 81297 HBr (Toronto Research Chemicals), N-methyl-d-aspartate (NMDA, Sigma-Aldrich), forskolin (Sigma-Aldrich), SCH 23390 HCl (Tocris) and U0126 (Tocris), were initially dissolved in DMSO to prepare stock solutions and then diluted to the desired concentration in artificial cerebrospinal fluid. For in vivo experiments, SKF 81297 HBr, quinpirole HCl and SCH 23390 HCl (Tocris) were dissolved in physiological saline and injected in a volume of 1 ml/kg. For 6-OHDA lesion experiments, desipramine HCl (Sigma-Aldrich), and pargyline (Sigma-Aldrich) were dissolved in physiological saline and injected at a volume of 1 ml/kg. 6-OHDA HBr (MilliporeSigma) was prepared at 7 µg/µl dissolved in 0.02% ascorbic acid and 0.9% NaCl, and stored at – 80 °C for up to 1 week prior to use. For dyskinesia experiments, l-DOPA methyl ester HCL and benserazide (Sigma) were dissolved in 0.9% saline with 0.1% ascorbate and injected s.c. at 1 ml/kg.